Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement

Levine, 2011, 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary, Circulation, 124, 2574, 10.1161/CIR.0b013e31823a5596 Mauri, 2014, Twelve or 30months of dual antiplatelet therapy after drug-eluting stents, N Engl J Med, 371, 2155, 10.1056/NEJMoa1409312 Jeremias, 2008, Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world', Coron Artery Dis, 19, 111, 10.1097/MCA.0b013e3282f34220 Venkitachalam, 2011, Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry, Circulation, 124, 1028, 10.1161/CIRCULATIONAHA.110.978593 Hannan, 2008, Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents, Circulation, 117, 2071, 10.1161/CIRCULATIONAHA.107.725531 JV, 2007, Effectiveness and safety of drug-eluting stents in Ontario, N Engl J Med, 357, 1393, 10.1056/NEJMoa071076 Beohar, 2007, Outcomes and complications associated with off-label and untested use of drug-eluting stents, JAMA, 297, 1992, 10.1001/jama.297.18.1992 Marroquin, 2008, A comparison of bare-metal and drug-eluting stents for off-label indications, N Engl J Med, 358, 342, 10.1056/NEJMoa0706258 Win, 2007, Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents, JAMA, 297, 2001, 10.1001/jama.297.18.2001 Daemen, 2008, Four-year clinical follow-up of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry, Am J Cardiol, 101, 1105, 10.1016/j.amjcard.2007.11.074 Lemos, 2004, Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry, Circulation, 109, 190, 10.1161/01.CIR.0000109138.84579.FA Stolker, 2010, Predicting restenosis in drug eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry, Circ Cardiovasc Interv, 3, 327, 10.1161/CIRCINTERVENTIONS.110.946939 Yeh, 2011, Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention, Circulation, 124, 1557, 10.1161/CIRCULATIONAHA.111.045229 Hong, 2006, Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes, Heart, 92, 1119, 10.1136/hrt.2005.075960 Singh, 2004, Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial, Circulation, 109, 2727, 10.1161/01.CIR.0000131898.18849.65 Gao, 2008, Safety and efficacy of the cypher select sirolimus-eluting stent in the “real world”—clinical and angiographic results from the China Cypher Select registry, Int J Cardiol, 125, 339, 10.1016/j.ijcard.2007.02.031 Lee, 2007, Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries, Catheter Cardiovasc Interv, 69, 821, 10.1002/ccd.21019 Jacob, 2005, Design of a registry to characterize “real-world” outcomes of percutaneous coronary revascularization in the drug-eluting stent era, Am Heart J, 150, 887, 10.1016/j.ahj.2005.03.030 Pencina, 2004, Overall c as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation, Stat Med, 23, 2109, 10.1002/sim.1802 Antolini, 2004, Inference on correlated discrimination measures in survival analysis: a nonparametric approach, Commun Stat Theory Methods, 33, 2117, 10.1081/STA-200026579 Pencina, 2008, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med, 27, 157, 10.1002/sim.2929 Candell-Riera, 2013, Usefulness of exercise test and myocardial perfusion-gated single photon emission computed tomography to improve the prediction of major events, Circ Cardiovasc Imaging, 6, 531, 10.1161/CIRCIMAGING.112.000158 Parikh, 2011, Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery, J Am Soc Nephrol, 22, 1737, 10.1681/ASN.2010111163 Hall, 2011, Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis, Clin J Am Soc Nephrol, 6, 2740, 10.2215/CJN.04960511 Jain, 2014, Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models, J Card Fail, 20, 577, 10.1016/j.cardfail.2014.06.001 Paynter, 2009, Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3, Ann Intern Med, 150, 65, 10.7326/0003-4819-150-2-200901200-00003 Piccini, 2010, Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction >35%, J Am Coll Cardiol, 56, 206, 10.1016/j.jacc.2010.01.061 Spertus, 2005, Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery, Circulation, 111, 768, 10.1161/01.CIR.0000155242.70417.60 Cutlip, 2002, Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials, J Am Coll Cardiol, 40, 2082, 10.1016/S0735-1097(02)02597-4 Kastrati, 1997, Predictive factors of restenosis after coronary stent placement, J Am Coll Cardiol, 30, 1428, 10.1016/S0735-1097(97)00334-3 Mercado, 2001, Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era, J Am Coll Cardiol, 38, 645, 10.1016/S0735-1097(01)01431-0 Stone, 2010, Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction) trial, J Am Coll Cardiol, 56, 1597, 10.1016/j.jacc.2010.08.608 Nowack, 2009, In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents, J Am Coll Cardiol Intv, 2, 767, 10.1016/j.jcin.2009.05.016 Stolker, 2012, Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year, Circ Cardiovasc Interv, 5, 772, 10.1161/CIRCINTERVENTIONS.111.967802 Kornowski, 2008, Drug-eluting stent in saphenous vein graft lesions, Catheter Cardiovasc Interv, 71, 894, 10.1002/ccd.21615 Okabe, 2008, Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts, Am J Cardiol, 102, 530, 10.1016/j.amjcard.2008.04.041 Vermeersch, 2007, Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial, J Am Coll Cardiol, 50, 261, 10.1016/j.jacc.2007.05.010 Mehilli, 2011, Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial, Lancet, 378, 1071, 10.1016/S0140-6736(11)61255-5 Bensley, 2013, Accuracy of administrative data versus clinical data to evaluate carotid endarterectomy and carotid stenting, J Vasc Surg, 58, 412, 10.1016/j.jvs.2013.01.010 Pasquali, 2013, Differential case ascertainment in clinical registry versus administrative data and impact on outcomes assessment for pediatric cardiac operations, Ann Thorac Surg, 95, 197, 10.1016/j.athoracsur.2012.08.074 Vaughan Sarrazin, 2012, Finding pure and simple truths with administrative data, JAMA, 307, 1433, 10.1001/jama.2012.404 Antman, 2000, The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making, JAMA, 284, 835, 10.1001/jama.284.7.835 Boersma, 2000, Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients: the PURSUIT Investigators, Circulation, 101, 2557, 10.1161/01.CIR.101.22.2557 Wilson, 1998, Prediction of coronary heart disease using risk factor categories, Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837 Cook, 2007, Use and misuse of the receiver operating characteristic curve in risk prediction, Circulation, 115, 928, 10.1161/CIRCULATIONAHA.106.672402 Hayward, 2006, Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis, BMC Med Res Methodol, 6, 18, 10.1186/1471-2288-6-18 Kent, 2010, Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal, Trials, 11, 85, 10.1186/1745-6215-11-85 Marso, 2010, Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention, JAMA, 303, 2156, 10.1001/jama.2010.708 Mehta, 2009, Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry, Circ Cardiovasc Interv, 2, 222, 10.1161/CIRCINTERVENTIONS.108.846741 Peterson, 2010, Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry, J Am Coll Cardiol, 55, 1923, 10.1016/j.jacc.2010.02.005 Arnold, 2008, Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decision making, Circ Cardiovasc Qual Outcomes, 1, 21, 10.1161/CIRCOUTCOMES.108.791863 Decker, 2008, Implementing an innovative consent form: the PREDICT experience, Implement Sci, 3, 58, 10.1186/1748-5908-3-58 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators, 1996, Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease, N Engl J Med, 335, 217, 10.1056/NEJM199607253350401 Serruys, 2009, For the SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease, N Engl J Med, 360, 961, 10.1056/NEJMoa0804626 Farkouh, 2012, For the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes, N Engl J Med, 367, 2375, 10.1056/NEJMoa1211585 Chakrabarti, 2014, Angiographic validation of the ACCF-STS Collaboration on the Comparative Effectiveness of Revascularization Strategies study, Circ Cardiovasc Interv, 7, 11, 10.1161/CIRCINTERVENTIONS.113.000679 Bonaa, 2016, Drug-eluting or bare-metal stents for coronary artery disease, N Engl J Med, 375, 1242, 10.1056/NEJMoa1607991 Kaiser, 2010, Drug-eluting versus bare-metal stents in large coronary arteries, N Engl J Med, 363, 2310, 10.1056/NEJMoa1009406 Sabaté, 2012, Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1year results of a randomised controlled trial, Lancet, 380, 1482, 10.1016/S0140-6736(12)61223-9